Abstract
Successful treatment of vascular anomalies has eluded the physician until now, despite various treatments utilised. Bleomycin has been successfully used in intralesional injection treatment of cystic hygromas and haemangiomas, based specifically on a high sclerosing effect on vascular endothelium. In a prospective study of 95 patients, the effectiveness of intralesional bleomycin injection (IBI) treatment in haemangiomas and vascular malformations was evaluated and documented. Complete resolution or significant improvement occurred in 80% of all patients treated. Complete resolution occurred in 49% of haemangiomas, 32% of venous malformations, and 80% of cystic hygromas. Significant improvement occurred in 38% of haemangiomas, 52% of venous malformations, 13% of cystic hygromas and 50% of lymphatic malformations. Of the six patients who presented with a painful lesion, four experienced complete resolution and two had significant improvement to treatment. Local complications encountered were superficial ulceration occurring in 2 patients, and cellulitis in 1 of the 95 patients. Systemic complications were flu-like symptoms in three patients and partial, transient hair loss in two patients. None of the patients presented with haematological toxic effects or signs of pulmonary involvement (fibrosis, hypertension). IBI is an effective treatment in haemangiomas and vascular malformation lesions, obviating the need for invasive primary surgery or systemic treatment regimens in 80% of cases, and allowing for limited need of secondary surgical or adjunctive procedures in cases with a moderate result.
Similar content being viewed by others
References
Umezawa H (1966) Purification of bleomycins. J Antibiot 19:21–215
Blum R (1973) A clinical review of Bleomycin—a new antineoplastic agent. Cancer 31:903–914
Lopez-larraza D (1990) The kinetics of DNA damage by bleomycin in mammalian cells. Mutation Research 232:57–61
Yura J (1977) Bleomycin treatment for cystic hygroma in children. Arch Jap Chir 5 (46): 607–614
Tanigawa N (1987) Treatment of cystic hygroma and lymphangioma with the use of Bleomycin fat emulsion. Cancer 15:741–749
Tanaka K (1990) Sclerosing therapy with Bleomycin emulsion for lymphangioma in children. Ped Surg Int 5:270–273
Okada A (1992) Injection of Bleomycin as a primary therapy of cystic lymphangioma. J Ped Surg 27 (4): 440–443
Orford J (1995) Bleomycin therapy for cystic hygroma. J Ped Surg 30 (9):1282–1287
Sarihan H (1997) A new treatment with Bleomycin for complicated cutaneous hemangioma in children. Eur J Ped Surg 7:158–162
Kullendorf C (1997) Efficacy of Bleomycin treatment for symptomatic hemangiomas in children. Ped Surg Int 12:526–528
Qin ZP (1998) Long term results of intratumorous Bleomycin-A5 injection for head and neck lymphangioma. Mosby Year Book 86 (2): 139–144
Enjolras O (1981) Classification and management of the various superficial vascular anomalies: hemangiomas and vascular malformations. J Dermatol 24:701–710
Mulliken JB (2000) Current problems in surgery. 37(8):517–584
Huston III J (1992) Magnetic resonance imaging of facial vascular anomalies. Mayo Clin Proc 67:739–747
Metry DW, Hebert AA, (2000) Benign cutaneous vascular tumours of infancy. Arch Dermatol.136:905–914
Sloan GM et al (1989) Intralesional corticosteroid therapy for infantile hemangiomas. Plast Reconstr Surg 83:459–467
Boon LM (1999) Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 104:1616–1623
Rogers M (2000) Treatment of ‘angiomas’:a modern commentary. Austral J Dermatol 41 [Suppl]:S89–S91
Weiss AH (1989) Adrenal suppression after corticosteroid injection of periocular hemangiomas. Am J Ophthalmol 107:518–522
Shorr N (1986) Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surg 14:229–231
Greinwald JH et al (1999) An update on the treatment of hemangiomas in children with interferon alpha-2a. Arch Otolaryngol Head Neck Surg 125:21–27
Scheepers JH et al (1995) Does the pulsed tunable laser have a role in the management of infantile hemangiomas? Observations based on 3 years’ experience.Plast Reconstr Surg 95:305–312
Drolet BA et al (1999) Hemangiomas in children. N Engl J Med 341:173–181
Berenguer B et al (1999) Sclerotherapy of craniofacial venous malformations:complications and results. Plast Reconstr Surg 104:1–11
Mason KP et al (2000) Serum ethanol levels in children and adults after ethanol embolisation or sclerotherapy for vascular anomalies. Radiology 217:127–132
Luce JK (1969) Clinical trial of bleomycin in solid tumors and lymphomas. Proc Am Assoc Cancer Res10:38
Muggia FM (1983) Pulmonary toxicity of antitumour agents. Cancer Tr Rev 10:221–243
Ugur Ö et al (1993) Bleomycin lung toxicity detected by technetium-99m diethylene triamine penta-acetic acid aerosol scintigraphy. Eur J Nucl Med 20:114–118
Gangopadhyay AN et al (1997) Role of steroid in childhood haemangioma: a 10 years review. Int Surg 82:49–51
Enjolras O et al (1990) Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics 85:491–498
Gelbert F et al (2000) Percutaneous sclerotherapy for venous malformation of the lips: a retrospective study of 23 patients. Interv Neurorad 42:692–696
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Muir, T., Kirsten, M., Fourie, P. et al. Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Ped Surgery Int 19, 766–773 (2004). https://doi.org/10.1007/s00383-003-1058-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00383-003-1058-6